Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Marketing in Brief: Senetek

This article was originally published in The Rose Sheet

Executive Summary

Senetek: VivaKin X, a botanically-based skin treatment line developed from the firm's "Factor X" technology, will be distributed in Asia through a recently signed exclusive agreement with Trans Eastern Capital Corp. Currently being sold in Norway, Finland, Sweden and Iceland, VivaKin X comes in cream and lotion form, and will be expanded over the next year to include a day moisturizer with sunblock, night cream, toner, eye gel, and hydra-intensive gel. In December 1990 the St. Louis-based Senetek signed an agreement giving Procter & Gamble exclusive worldwide rights for the development and sale of products using Factor X ("The Rose Sheet" Jan. 14, 1991, p. 5). Senetek, believing that VivaKin X/Factor X is a cosmetic, terminated the agreement because it objected to P&G's development of the technology as a drug in the U.S., the firm explained...
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS001615

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel